卢旺达宫颈癌治疗:资源驱动的适应性调整、质量指标与患者结局
本研究为回顾性队列研究,纳入2016年4月至2018年6月卢旺达新诊断宫颈癌患者379例,中位年龄54岁,21%合并HIV感染,55%为III或IV期。接受根治性子宫切除术者3年无事件生存率为90%(95%CI 72-97%),接受放化疗者为66%(95%CI 55-75%),仅接受化疗者为12%(95%CI 6-20%)。数据支持在预计放化疗延迟时使用暂时性化疗。
要点
- 379例宫颈癌患者中55%为III/IV期,21%合并HIV感染。
- 根治性子宫切除术3年无事件生存率90%,放化疗66%,仅化疗12%。
- 等待放化疗期间接受卡铂/紫杉醇者与直接放化疗者生存无差异。
核心结论
- 通过协调护理和务实方法,多模式治疗在低资源环境下对宫颈癌有效。
- 数据支持在预计放化疗延迟时使用暂时性化疗。
- 迫切需要可持续的妇科肿瘤手术机会和扩大放疗可及性。
研究设计与样本
- 回顾性队列研究,纳入2016年4月至2018年6月所有新诊断宫颈癌患者,共379例。
- 数据从医疗记录中提取,采用描述性统计、Kaplan-Meier法和Cox比例风险回归分析。
主要发现
- 379例患者中位年龄54岁,21%合并HIV感染,55%为III或IV期。
- 34例早期患者接受根治性子宫切除术。
- 254例被加入放化疗等待名单,其中114例最终接受放化疗;30例(26%)在诊断后中位126天直接接受放化疗,83例(73%)在等待期间接受卡铂/紫杉醇,诊断至化疗中位56天,至放化疗中位207天。
- 直接放化疗与先化疗亚组之间无生存差异。
- 大多数化疗接受者(77%)报告症状改善。
临床怎么用
- 作者认为数据支持在预计放化疗延迟时使用暂时性化疗。
- 作者指出迫切需要可持续的妇科肿瘤手术机会和扩大放疗可及性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Most cervical cancer cases and deaths occur in low- and middle-income countries, yet clinical research from these contexts is significantly underrepresented. We aimed to describe the treatment quality, resource-driven adaptations, and outcomes of cervical cancer patients in Rwanda. METHODS: A retrospective cohort study was conducted of all patients with newly diagnosed cervical cancer enrolled between April 2016 and June 2018. Data were abstracted from medical records and analyzed using descriptive statistics, Kaplan Meier methods, and Cox proportional hazards regression. RESULTS: A total of 379 patients were included; median age 54 years, 21% HIV-infected. A majority (55%) had stage III or IV disease. Thirty-four early-stage patients underwent radical hysterectomy. Of 254 patients added to a waiting list for chemoradiation, 114 ultimately received chemoradiation. Of these, 30 (26%) received upfront chemoradiation after median 126 days from diagnosis, and 83 (73%) received carboplatin/paclitaxel while waiting, with a median 56 days from diagnosis to chemotherapy and 207 days to chemoradiation. There was no survival difference between the upfront chemoradiation and prior chemotherapy subgroups. Most chemotherapy recipients (77%) reported improvement in symptoms. Three-year event-free survival was 90% with radical hysterectomy (95% CI 72-97%), 66% with chemoradiation (95% CI 55-75%), and 12% with chemotherapy only (95% CI 6-20%). CONCLUSIONS: Multi-modality treatment of cervical cancer is effective in low resource settings through coordinated care and pragmatic approaches. Our data support a role for temporizing chemotherapy if delays to chemoradiation are anticipated. Sustainable access to gynecologic oncology surgery and expanded access to radiotherapy are urgently needed.
引用
- DeBoer RJ, Umutoni V, Bazzett-Matabele L, et al. Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes. Gynecol Oncol. 2021. PMID: 34916066. doi:10.1016/j.ygyno.2021.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。